Marta Vallee Cobham
Publications by Year
Research Areas
MicroRNA in disease regulation, Cancer, Hypoxia, and Metabolism, Radiopharmaceutical Chemistry and Applications, Inflammatory mediators and NSAID effects, Microbial metabolism and enzyme function
Most-Cited Works
- → Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases(2016)219 cited
- → Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer(2021)92 cited
- → Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity(2015)69 cited
- → Phase 1/2 Clinical Trial of Interferon α2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma(2007)50 cited
- → Incremental increase in VEGFR1+ hematopoietic progenitor cells and VEGFR2+ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients(2011)31 cited
- → Ixabepilone‐induced mitochondria and sensory axon loss in breast cancer patients(2014)30 cited
- → Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer(2009)29 cited
- → Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases(2020)14 cited
- → Abstract 4720: Incremental increase in VEGFR1+ and VEGFR2+ hemangiogenic progenitor cells predict relapse and tumor response in breast cancer (BC) patients(2011)1 cited
- → Abstract LB-349: Copper depletion as a strategy to affect the tumor microenvironment in breast cancer patients at high risk of relapse and in triple negative preclinical models of breast cancer: Updated results of a phase II study of tetrathiomolybdate (TM) in breast cancer (BC) patients (pts) at high risk for recurrence(2016)1 cited